In the critical and consistently high-demand field of orthopedics and endocrinology, products that offer reliability and proven efficacy are essential. Terifix Injection, with its Teriparatide (600mcg) formulation, is a best-in-class product for the treatment of severe osteoporosis in individuals at a high risk for fracture. As a PCD pharma company, we recognize the significant and continuous demand for such specialized products, making this a valuable asset for any pharma distributor or wholesaler.
Teriparatide is a powerful anabolic agent that stimulates new bone formation, unlike most osteoporosis medications that only slow down bone loss. Its unique mechanism of action makes it a crucial tool for healthcare professionals in managing patients with high-risk fractures. The injectable form ensures precise dosing and rapid bioavailability, which is critical for effective therapy.
At Cafoli Lifecare, we are committed to providing our B2B pharma partners with high-quality, profitable products. Our Terifix Injection is manufactured under strict quality controls and comes with a competitive pricing structure. By partnering with us, you gain access to a reliable supply of this essential medication and the comprehensive support needed to succeed in the wholesale pharma market. Choose this product to build a strong and reputable business in the specialized orthopedic segment.
Common side effects of Terifix Injection may include nausea, leg cramps, dizziness, headache, and pain at the injection site. Some patients may also experience transient increases in calcium levels shortly after administration. Rare but serious side effects include orthostatic hypotension, especially after the first few doses, and very rarely, prolonged use has been associated with an increased risk of osteosarcoma in animal studies. However, this risk in humans is extremely low when used as recommended.
Terifix Injection is indicated for the treatment of osteoporosis in postmenopausal women, men at high risk of fracture, and patients with glucocorticoid-induced osteoporosis who are at increased risk for bone fractures. It contains Teriparatide, a recombinant form of human parathyroid hormone (PTH 1-34), which helps stimulate new bone formation, increases bone mineral density (BMD), and reduces the risk of vertebral and non-vertebral fractures. It is especially recommended in patients who have failed or are intolerant to previous osteoporosis treatments.
Terifix Injection is typically administered as a once-daily subcutaneous injection in the thigh or abdomen, under the guidance of a healthcare provider. The total treatment duration should not exceed 24 months over a patient’s lifetime. Regular monitoring of calcium levels, renal function, and vitamin D status is advised during treatment. Terifix is not recommended in patients with bone malignancies, Paget’s disease, hypercalcemia, or those who have received radiation therapy to bones. Patients should remain seated or lying down for a few minutes after administration to reduce the risk of dizziness or fainting.
Store Terifix Injection in a refrigerator at 2°C to 8°C. Do not freeze. Keep the pen/cartridge tightly closed when not in use and protect it from direct light. Once opened, the multi-dose pen can typically be used for up to 28 days, as per manufacturer’s instructions. Always keep it out of reach of children, and dispose of needles properly after use.